==== Front J Cancer Res Clin Oncol J Cancer Res Clin Oncol Journal of Cancer Research and Clinical Oncology 0171-5216 1432-1335 Springer Berlin Heidelberg Berlin/Heidelberg 35871700 4215 10.1007/s00432-022-04215-7 Research Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer Takeuchi Eiji eijitake1964@icloud.com 1 Kondo Kensuke sdt4260@gmail.com 2 Okano Yoshio okano.yoshio.mu@mail.hosp.go.jp 3 Kunishige Michihiro michi6910@gmail.com 3 Kondo Yoshihiro bontakundog@gmail.com 3 Kadota Naoki naoki_kadota.usa@kta.biglobe.ne.jp 3 Machida Hisanori hsnr1967mcd@gmail.com 3 Hatakeyama Nobuo nobuoh1965@gmail.com 3 Naruse Keishi naruse.keishi.hj@mail.hosp.go.jp 4 Ogino Hirokazu ogino@tokushima-u.ac.jp 2 Nokihara Hiroshi hnokihara@hosp.ncgm.go.jp 2 Shinohara Tsutomu shinohara_fau@yahoo.co.jp 5 Nishioka Yasuhiko yasuhiko@tokushima-u.ac.jp 2 1 Department of Clinical Investigation, National Hospital Organization Kochi Hospital, 1-2-25 Asakuranishimachi, Kochi, Kochi 780-8507 Japan 2 grid.267335.6 0000 0001 1092 3579 Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, 770-8503 Japan 3 Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, 1-2-25 Asakuranishimachi, , Kochi, Kochi 780-8507 Japan 4 Department of Pathology, National Hospital Organization Kochi Hospital, 1-2-25 Asakuranishimachi, Kochi, Kochi 780-8507 Japan 5 grid.267335.6 0000 0001 1092 3579 Department of Community Medicine for Respirology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, 770-8503 Japan 24 7 2022 24 7 2022 2023 149 7 31393147 6 4 2022 15 7 2022 © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Purpose Immune checkpoint inhibitors (ICI) are a promising treatment, but may cause hyperprogressive disease and early death. The present study investigated early mortality factors in ICI monotherapy for lung cancer. Patients and methods We retrospectively reviewed all patients diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) and treated with ICI monotherapy (nivolumab, pembrolizumab, and atezolizumab) between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University. Early death was defined as patients who died within 60 days of ICI treatment. Results A total of 166 patients were included. The majority of patients (87%) had an Eastern cooperative oncology group (ECOG) Performance status (PS) of 0/1. There were 21 early deaths. Significant differences were observed in ECOG PS, the histological type, liver metastasis, tumor size, the white blood cell count, neutrophils (%), lymphocytes (%), the neutrophil-to-lymphocyte ratio in serum (sNLR), C-reactive protein (CRP), and albumin between the groups with or without early death. Univariate logistic regression analyses identified ECOG PS score ≥ 2, liver metastasis, tumor size ≥ 5 cm, neutrophils ≥ 69%, lymphocytes < 22%, sNLR ≥ 4, CRP ≥ 1 mg/dl, and albumin < 3.58 g/dl as significant risk factors for early death. A multivariate logistic regression analysis revealed that liver metastasis (Odds ratio [OR], 10.3; p = 0.008), ECOG PS score ≥ 2 (OR, 8.0; p = 0.007), and a smoking history (OR, 0.1; p = 0.03) were significant risk factors for early death. Conclusion Liver metastases, ECOG PS score ≥ 2, and a non-smoking history are early mortality factors in ICI monotherapy for advanced or metastatic NSCLC. Keywords Early death Early mortality factors Immune checkpoint inhibitors Lung cancer Monotherapy issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2023 ==== Body pmcIntroduction Immune checkpoint inhibitors (ICI) have caused a paradigm shift in the treatment of various cancer types. ICI monotherapy has been used as a first-line treatment for advanced or metastatic untreated non-small cell lung cancer (NSCLC) (Reck et al. 2016; Mok et al. 2019). Among patients with advanced, previously treated NSCLC, overall survival (OS) was shown to be significantly better with ICI monotherapy than with chemotherapy (Borghaei et al. 2015; Brahmer et al. 2015; Herbst et al. 2016; Rittmeyer et al. 2017). On the other hand, ICI have been implicated in the development of hyperprogressive disease (HPD) and early death (Champiat et al. 2017; Abbar et al. 2021; Ferrara et al. 2018). Although the risk factors for and mechanisms underlying HPD have been examined (Lo Russo et al. 2019; Kim et al. 2020, 2021; Castello et al. 2020; Passaro et al. 2021; Chen et al. 2021; Ku et al. 2021; Kamada et al. 2019), current knowledge is still insufficient. The selection of suitable patients for ICI monotherapy is essential. OS is the most robust indicator of cancer treatment outcomes. On the other hand, few studies have examined early mortality factors in ICI monotherapy for advanced or metastatic lung cancer in real-world settings. To the best of our knowledge, only one study investigated early death in real-world settings (Inoue et al. 2018). Therefore, the present study attempted to identify early mortality factors in ICI monotherapy for advanced or metastatic NSCLC. Materials and methods Patients We retrospectively reviewed all patients diagnosed with advanced or metastatic NSCLC and treated with ICI monotherapy (nivolumab, pembrolizumab, and atezolizumab) between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University. Early death was defined as patients who died within 60 days of ICI treatment. Data collection We collected data on age, sex, smoking history, the Eastern cooperative oncology group performance scale (ECOG PS), white blood cell count, neutrophil count, lymphocyte count, eosinophil count, C-reactive protein (CRP), albumin, histological type, the genotypes of mutations, type of ICI, line of ICI, date of ICI initiation, number of ICI administered, and the status of death. We also examined data obtained on the primary lesion size (maximum diameter measured on chest computed tomography), the number of metastatic sites (count of involved solid organs, not all sites), the status of specific metastasis (non-regional lymph nodes, contralateral lung, pleura, brain, liver, kidney, adrenal gland, and bone), and stage (according to the eighth edition of the tumor-node-metastasis [TNM] staging system). A computed tomography scan was performed for a radiological evaluation before ICI therapy. Statistical analysis Categorical and continuous variables were summarized using descriptive statistics. The independent samples t test was used to test for differences between continuous variables. Pearson’s chi-squared test and Fisher’s exact test were employed to analyze relationships between categorical variables. Univariate and multivariate logistic regression analyses were performed to identify predictive factors associated with early death with ICI. The neutrophil-to-lymphocyte ratio in serum (sNLR) was calculated as the ratio of the neutrophil count to the lymphocyte count. The cut-off value for sNLR was set at 4 based on previous studies (Kim et al. 2019b; Sacdalan et al. 2018). We conducted all statistical analyses using SPSS statistics version 27.0 (IBM, Armonk, USA). P values are presented without adjustments for multiple comparisons in an exploratory manner. Results Patient characteristics A total of 166 advanced or metastatic NSCLC patients treated with ICI monotherapy were included in the present study. Twenty-one out of 166 patients (13%) died within 60 days. Twenty patients (95%) died early due to the rapid progression of lung cancer. One patient (5%) died of immune-related adverse events, including interstitial lung disease. No patient died from exacerbation of complications or other diseases. The clinical characteristics of enrolled patients are summarized in Table 1. Among 166 patients, mean age at ICI therapy was 69 years, 128 (77%) were male, and 130 (78%) were ex- or current smokers. Most patients (87%) had ECOG PS of 0–1. Twenty-one patients (13%) had postoperative recurrence, 31 (17%) had stage III, and 114 (69%) had stage IV. Ninety-eight patients (59%) exhibited adenocarcinoma histology, while 45 (27%) showed squamous cell carcinoma histology. The expression of PD-L1 was higher than 1% in 80% (132/166) of patients, but was absent in 19% (31/166). Six patients (4%) were harboring epidermal growth factor receptor (EGFR) mutations, two (1%) had the anaplastic lymphoma kinase (ALK) rearrangement, and one each (1%) harbored rearranged during transfection (RET) and ROS proto-oncogene 1 (ROS1) fusion. Forty-five patients (27%) received ICI as the first-line therapy. Sixteen patients (10%) had liver metastasis.Table 1 Characteristics of the study population Total  ≤ 60 days  > 60 days p n = 166 n = 21 n = 145 Age, y Mean age, (SD) 69 (9) 68 (10) 69 (9) 0.9* Sex, n (%) Male 128(77) 14 (67) 114 (79) 0.2*** Female 38 (23) 7 (33) 31 (21) Smoking history, n (%) Yes 130 (78) 13 (61) 117 (81) 0.1*** No 30 (18) 6 (29) 24 (17) Missing 6 (4) 2 (10) 4(3) ECOG PS, n (%) 0–1 145 (87) 10 (48) 135 (93) 0.001*** 2–4 21 (13) 11 (52) 10 (7) Stage, n (%) Recurrence 21 (13) 2 (10) 19 (13) 0.4*** III 31 (17) 2 (10) 29 (20) IV 114 (69) 17 (81) 97 (67) Histological type, n (%) Adeno 98 (59) 16 (76) 82 (57) 0.047*** Squamous 45 (27) 1 (5) 44 (30) Others 23 (14) 4 (19) 19 (13) PD-L1, n (%)  < 1% 31 (19) 5 (24) 26 (18) 0.7***  ≥ 1% 132 (80) 16 (76) 116 (80) Missing 3 (2) 0 (0) 3 (3) Driver mutation, n (%) None 151 (91) 19 (90) 132 (91) 0.6*** EGFR 6 (4) 2 (10) 4 (3) ALK 2 (1) 0(0) 2(1) RET 1 (1) 0 (0) 1 (1) ROS1 1(1) 0 (0) 1 (1) Missing 5 (3) 0 (0) 5 (3) Treatment line, n (%) 1 45 (27) 4 (19) 41 (28) 0.4**  > 1 121 (73) 17 (81) 104 (72) ICI drug, n (%) Pembrolizumab 130 (78) 17 (81) 113 (78) 0.9*** Nivolumab 35 (21) 4 (19) 31 (21) Atezolizumab 1 (1) 0 (0) 1 (1) Liver metastasis, n (%) No 150 (90) 14 (76) 136 (96)  < 0.001*** Yes 16 (10) 7 (24) 9 (4) Tumor size, mm Mean, (SD) 43.7 (24.1) 56.3 (25.2) 41.8 (23.5) 0.01* White blood count, /μL Mean, (SD) 7229 (3404) 9905 (4657) 6842 (3011) 0.01* Neutrophils, % Mean, (SD) 67 (10) 72 (8) 66 (10) 0.004* Lymphocytes, % Mean, (SD) 22 (9) 15 (5) 23 (9)  < 0.001* sNLR, ratio Mean, (SD) 3.9 (2.5) 5.6 (2.5) 3.7 (2.4)  < 0.001* Eosinophils, % Mean, (SD) 3 (3) 4 (5) 3 (3) 0.5* CRP, mg/dL Mean, (SD) 2.6 (3.4) 4.9 (4.9) 2.3 (3.1) 0.03* Alb, g/dL Mean, (SD) 3.5 (0.7) 2.7 (0.7) 3.6 (0.6)  < 0.001* ECOG PS Eastern cooperative oncology group performance status, PD-L1 programmed death ligand 1, EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, RET rearrangement during transfection, ROS1 ROS proto-oncogene 1, ICI immune checkpoint inhibitor, sNLR the neutrophil-to-lymphocyte ratio in serum, CRP C-reactive protein, Alb albumin *Independent samples t test, **Fisher’s exact test, ***Chi-squared test Among the 21 patients who died early, mean age was 68 years, 14 (67%) were male, and thirteen (61%) were ex- or current smokers. Ten patients (48%) had an ECOG PS of 0–1. Two patients (10%) had postoperative recurrence, two (10%) had stage III, and 17 (81%) had stage IV. Sixteen patients (76%) showed adenocarcinoma histology, and one (5%) exhibited squamous cell carcinoma histology. The expression of PD-L1 was higher than 1% in 76% (16/21) of patients, but was absent in 24% (5/21). Two patients (10%) harbored EGFR mutations. Four patients (19%) received ICI as the first-line therapy, and seven (24%) had liver metastasis. Among the 145 patients without early death, mean age was 69 years, 114 (79%) were male, and 117 (81%) were ex- or current smokers. One hundred and thirty-five patients (93%) had an ECOG PS of 0–1. Nineteen patients (13%) had postoperative recurrence, 29 (20%) had stage III, and 97 (67%) had stage IV. Eighty-two patients (57%) exhibited adenocarcinoma histology, and 44 (30%) showed squamous cell carcinoma histology. The expression of PD-L1 was higher than 1% in 80% of patients (116/145), but was absent in 18% (26/145). Four patients (3%) harbored EGFR mutations, two (1%) had the ALK rearrangement, and one each (1%) harbored RET and ROS1 fusion. Forty-one patients (28%) received ICI as the first-line therapy. Nine (4%) had liver metastasis. Significant differences were observed in ECOG PS, the histological type, liver metastasis, tumor size, the white blood count, neutrophils (%), lymphocytes (%), sNLR, CRP, and albumin between the groups with or without early death. Univariate analysis of factors associated with early death As shown in Table 2, univariate logistic regression analyses identified ECOG PS score ≥ 2 (Odds ratio [OR], 14.9; 95% CI, 5.1–43.3; p < 0.001), liver metastasis (OR, 7.6; 95% CI, 2.4–23.4; p < 0.001), tumor size ≥ 5 cm (OR, 2.6; 95% CI, 1.03–6.6; p = 0.04), neutrophils ≥ 69% (OR, 3.5; 95% CI, 1.3–9.7; p = 0.01), lymphocytes < 22% (OR, 10.1; 95% CI, 2.3–45.3; p = 0.002), sNLR ≥ 4 (OR, 4.2; 95% CI, 1.6–11; p = 0.004), CRP ≥ 1 mg/dl (OR, 6.6; 95% CI, 1.9–23.4; p = 0.003), and Alb < 3.58 g/dl (OR, 3.5; 95% CI, 1.5–7.7; p = 0.002) as significant risk factors for early death during ICI monotherapy.Table 2 Univariate analysis of factors associated with early death Variable Category Univariate analysis Odds ratio (95% CI) p value Smoking history No 1 0.1 Yes 0.4 (0.2–1.3) ECOG PS 0–1 1  < 0.001 2–4 14.9 (5.1–43.3) Histological type Non-adeno 1 0.1 Adeno 2.5 (0.9–7.1) PD-L1  ≥ 1% 1 0.7  < 1% 1.3 (0.4–3.7) Liver metastasis No 1  < 0.001 Yes 7.6 (2.4–23.4) Tumor size  < 5 cm 1 0.04  ≥ 5 cm 2.6 (1.03–6.6) Neutrophils  < 69% 1 0.01  ≥ 69% 3.5 (1.3–9.7) Lymphocytes  ≥ 22% 1 0.002  < 22% 10.1 (2.3–45.3) sNLR  < 4 1 0.004  ≥ 4 4.2 (1.6–11) Eosinophils  ≥ 1.5% 1 0.08  < 1.5% 2.3 (0.9–5.8) CRP  < 1 mg/dl 1 0.003  ≥ 1 mg/dl 6.6 (1.9–23.4) Alb  ≥ 3.58 g/dl 1 0.002  < 3.58 g/dl 3.5 (1.5–7.7) p values <0.05 are bolded ECOG PS Eastern cooperative oncology group performance status, adeno, adenocarcinoma, PD-L1 programmed death ligand 1, sNLR the neutrophil-to-lymphocyte ratio in serum, CRP C-reactive protein, Alb albumin Multivariate analysis of factors associated with early death A multivariate logistic regression analysis for the prediction of early death was performed using the following variables: a smoking history, ECOG PS, the histological type, liver metastasis, tumor size, neutrophils, lymphocytes, sNLR, CRP, and albumin (Table 3). A multivariate analysis with a multivariate logistic regression model showed that liver metastasis (OR, 10.3; 95% CI, 1.8–58; p = 0.008), ECOG PS score ≥ 2 (OR, 8.0; 95% CI, 1.8–36; p = 0.007), and a smoking history (OR, 0.1; 95% CI, 0.01–0.8; p = 0.03) were significant risk factors for early death during ICI monotherapy.Table 3 Multivariate analysis of factors associated with early death Variable Category Multivariate analysis Odds ratio (95% CI) p value Smoking history No 1 0.03 Yes 0.1(0.01–0.8) ECOG PS 0–1 1 0.007 2–4 8.0 (1.8–36) Histological type Non-adeno 1 0.1 Adeno 3.7 (0.7–18.8) Liver metastasis No 1 0.008 Yes 10.3 (1.8–58) Tumor size  < 5 cm 1 0.3  ≥ 5 cm 2.5 (0.5–12.5) Neutrophils  < 69% 1 0.7  ≥ 69% 0.7 (0.1–4.5) Lymphocytes  ≥ 22% 1 0.3  < 22% 3.5 (0.3–40) sNLR  < 4 1 0.8  ≥ 4 1.1 (0.2–6.8) CRP  < 1 mg/dl 1 0.2  ≥ 1 mg/dl 5.0 (0.5–48.6) Alb  ≥ 3.58 g/dl 1 0.1  < 3.58 g/dl 2.9 (0.7–11.4) p values <0.05 are bolded ECOG PS Eastern cooperative oncology group performance status, adeno, adenocarcinoma, sNLR the neutrophil-to-lymphocyte ratio in serum, CRP C-reactive protein, Alb albumin The number of early mortality factors and percentage of early deaths Liver metastases, ECOG PS score ≥ 2, and a non-smoking history were early mortality factors in ICI monotherapy against advanced or metastatic NSCLC. The number of early mortality factors and percentage of early deaths are shown in Fig. 1. One patient had all three early mortality factors, and the early mortality rate was 100%. Eight out of 11 patients (73%) with two early mortality factors and 7 out of 48 patients (15%) with one early mortality factor died within 60 days. Furthermore, 5 out of 106 patients (4.7%) with no early mortality factors died early.Fig. 1 The number of early mortality factors and percentage of early deaths Discussion The present results identified liver metastases, ECOG PS score ≥ 2, and a non-smoking history as early mortality factors in ICI monotherapy for advanced or metastatic NSCLC. Few studies have examined early mortality factors in ICI monotherapy for advanced or metastatic lung cancer in real-world settings. To the best of our knowledge, only one study investigated early mortality in real-world settings (Inoue et al. 2018). ICI has caused a paradigm shift in the treatment of various cancer types, but have also been implicated in the development of HPD and early patient death (Champiat et al. 2017; Abbar et al. 2021; Ferrara et al. 2018). Although the risk factors for and mechanisms underlying HPD have been examined (Lo Russo et al. 2019; Kim et al. 2020, 2021; Castello et al. 2020; Passaro et al. 2021; Chen et al. 2021; Ku et al. 2021; Kamada et al. 2019), current knowledge is still inadequate. Although PD-L1 and the tumor mutation burden (TMB) have been used as predictive biomarkers for ICI therapy, there are currently no established predictive biomarkers (Brody et al. 2017; Zou et al. 2021). The selection of suitable patients for ICI monotherapy is essential in real-world settings, and OS is the most robust indicator of cancer treatment outcomes. Therefore, we examined early mortality factors in ICI monotherapy for advanced or metastatic NSCLC in real-world settings. ECOG PS ≥ 2, a pretreatment CRP-to-albumin ratio > 0.3, and poor responses to previous treatment have been associated with early death in ICI monotherapy (Inoue et al. 2018). In the present study, a multivariate analysis with a multivariate logistic regression model identified liver metastasis (OR, 10.3; 95% CI, 1.8–58; p = 0.008), ECOG PS score ≥ 2 (OR, 8.0; 95% CI, 1.8–36; p = 0.007), and a smoking history (OR, 0.1; 95% CI, 0.01–0.8; p = 0.03) as risk factors for early death in ICI monotherapy. ECOG PS ≥ 2 is frequently identified as an early mortality factor. In a system review, liver metastasis, previous metastatic sites > 2, a Royal Marsden Hospital score ≥ 2, higher ECOG PS, and a lactate dehydrogenase (LDH) level greater than the normal upper limit were associated with the development of HPD (Chen et al. 2020). In another system review, liver metastasis, LDH, more than two metastatic sites, and a Royal Marsden Hospital score of 2 or higher correlated with HPD (Kim et al. 2019a). A previous study also implicated hepatic metastases, more than two metastatic sites, ECOG PS ≥ 2, and an LDH level higher than the normal upper limit in the development of HPD (Chen et al. 2021). Furthermore, liver metastasis was the only variable associated with HPD in a multivariate analysis (Abbar et al. 2021). The presence of tumors within the liver was previously shown to significantly reduce systemic tumor-specific immunity, and immunosuppression was dependent on regulatory T cells (Tregs) (Lee et al. 2020). The number of circulating Tregs was significantly higher than the baseline in patients with HPD (Kang et al. 2022). The balanced expression of PD-1 between CD8 + T cells and Tregs is essential in programmed cell death 1 (PD-1) inhibitory immunotherapy (Aksoylar and Boussiotis 2020; Kumagai et al. 2020). In a mouse model of liver metastasis due to colorectal cancer, Treg numbers were elevated, and the hepatocyte growth factor/hepatocyte growth factor receptor signaling pathway was up-regulated (Huang et al. 2020). Lactic acid has been shown to promote the expression of PD-1 in Tregs in highly glycolytic tumors, such as liver metastases (Kumagai et al. 2022). In the present study, a non-smoking history was a significant early mortality factor. OR was 0.1 (P = 0.03) when six patients with a missing smoking history were assumed to have a smoking history and 0.2 (P = 0.03) when they were hypothesized to have a non-smoking history, indicating that non-smoking history is a risk factor regardless of the presence or absence of missing data. The reason for this result is not apparent. In adenocarcinoma, a non-smoking status was predictive of a low TMB (Sharpnack et al. 2020). The probability of EGFR mutations and ALK rearrangements was previously shown to be significantly higher in patients with a non-smoking history than in those with a smoking history (Chapman et al. 2016). Furthermore, TMB was lower in EGFR-mutant lung cancer than in EGFR wild-type lung cancer (Offin et al. 2019). EGFR mutations and ALK rearrangements are generally associated with low response rates to ICI therapy in NSCLC (Gainor et al. 2016; Lee et al. 2017). Therefore, ICI may be less effective in patients with a non-smoking history. However, in the present study, only 2 out of 21 patients who died early had EGFR mutations and no ALK rearrangement. No significant differences were observed in genetic abnormalities between the groups with and without early death (Table 1). Specific molecular alterations (MDM2/MDM4, KRAS, and serine/threonine kinase 11) have been associated with HPD (Kato et al. 2017; Kim et al. 2019b). Therefore, these genetic abnormalities in patients with a non-smoking history may be related; however, only a few have been examined to date. The limitation of the present study is that it was a two-center retrospective analysis conducted with heterogeneous data from patient cohorts. Therefore, the results obtained are speculative and not definitive. Furthermore, since the number of cases was small, OR was significant, but CI was also large; therefore, reliability was not high. The frequency of early death within 60 days of ICI monotherapy for advanced or metastatic NSCLC was not high. Therefore, multicenter studies are needed. Although we need to consider these limitations when interpreting the present results, this study is of value because early mortality factors in ICI monotherapy against advanced or metastatic NSCLC were identified in real-world settings. Simple clinical parameters may easily predict early mortality with single-agent ICI against advanced or metastatic NSCLC and are clinically useful. Early mortality rates were 73 and 100% in patients with 2 and 3 early mortality factors, respectively. ICI-based combination therapy may be a better treatment option for patients with multiple mortality factors than ICI monotherapy for advanced or metastatic NSCLC. Conclusion Liver metastases, ECOG PS score ≥ 2, and a non-smoking history were identified as early mortality factors in ICI monotherapy against advanced or metastatic NSCLC. Abbreviations ALK Anaplastic lymphoma kinase CI Confidence interval CRP C-reactive protein ECOG Eastern Cooperative oncology group EGFR Epidermal growth factor receptor HPD Hyperprogressive disease ICI Immune checkpoint inhibitors LDH Lactate dehydrogenase NSCLC Non-small cell lung cancer PD-1 Programmed cell death 1 PD-L1 Programmed death ligand 1 OR Odds ratio OS Overall survival PS Performance status RET Rearranged during transfection ROS1 ROS proto-oncogene 1 Tregs Regulatory T cells sNLR Neutrophil-to-lymphocyte ratio in serum TMB Tumor mutation burden Acknowledgements We thank Hiroki Yoshida (Data Seed Inc.) for statistical advice. Author contributions Conceptualization and design: ET, HN; data collection and analysis: KK, YO, MK, YK, NK, HM, NH, TS, KN, HO; formal analysis and investigation: HM, ET; writing–original draft preparation: ET; writing–review and editing: HN, YN]; supervision: TS, HN, YN. All authors read and approved the final manuscript. Funding None. Data availability None. Code availability None. Declarations Competing interests The authors declare no competing interests. Conflict of interest The authors declare no conflicts of interest. Ethical approval The Institutional Review Board of the National Hospital Organization Kochi Hospital (R3-3) and Tokushima University (3013–3) approved the study protocol. Informed consent was waived because of the retrospective nature of the study. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. ==== Refs References Abbar B De Castelbajac V Gougis P Assoun S Pluvy J Tesmoingt C Théou-Anton N Cazes A Namour C Khalil A Gounant V Besse B Zalcman G Brosseau S Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors Lung Cancer 2021 152 109 118 10.1016/j.lungcan.2020.12.026 33385736 Aksoylar HI Boussiotis VA PD-1(+) T(reg) cells: a foe in cancer immunotherapy? Nat Immunol 2020 21 1311 1312 10.1038/s41590-020-0801-7 32973361 Borghaei H Paz-Ares L Horn L Spigel DR Steins M Ready NE Chow LQ Vokes EE Felip E Holgado E Barlesi F Kohlhaufl M Arrieta O Burgio MA Fayette J Lena H Poddubskaya E Gerber DE Gettinger SN Rudin CM Rizvi N Crino L Blumenschein GR Jr Antonia SJ Dorange C Harbison CT Graf Finckenstein F Brahmer JR Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 2015 373 1627 1639 10.1056/NEJMoa1507643 26412456 Brahmer J Reckamp KL Baas P Crino L Eberhardt WE Poddubskaya E Antonia S Pluzanski A Vokes EE Holgado E Waterhouse D Ready N Gainor J Aren Frontera O Havel L Steins M Garassino MC Aerts JG Domine M Paz-Ares L Reck M Baudelet C Harbison CT Lestini B Spigel DR Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 2015 373 123 135 10.1056/NEJMoa1504627 26028407 Brody R Zhang Y Ballas M Siddiqui MK Gupta P Barker C Midha A Walker J PD-L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review Lung Cancer 2017 112 200 215 10.1016/j.lungcan.2017.08.005 29191596 Castello A Rossi S Mazziotti E Toschi L Lopci E Hyperprogressive disease in patients with non-small cell lung cancer treated with checkpoint inhibitors: the role of (18) F-FDG PET/CT J Nucl Med 2020 61 821 826 10.2967/jnumed.119.237768 31862803 Champiat S Dercle L Ammari S Massard C Hollebecque A Postel-Vinay S Chaput N Eggermont A Marabelle A Soria JC Ferte C Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1 Clin Cancer Res 2017 23 1920 1928 10.1158/1078-0432.CCR-16-1741 27827313 Chapman AM Sun KY Ruestow P Cowan DM Madl AK Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers Lung Cancer 2016 102 122 134 10.1016/j.lungcan.2016.10.010 27987580 Chen Y Hu J Bu F Zhang H Fei K Zhang P Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis BMC Cancer 2020 20 707 10.1186/s12885-020-07206-4 32727409 Chen S Gou M Yan H Fan M Pan Y Fan R Qian N Dai G Hyperprogressive disease caused by PD-1 inhibitors for the treatment of pan-cancer Dis Markers 2021 2021 6639366 10.1155/2021/6639366 34239621 Ferrara R Mezquita L Texier M Lahmar J Audigier-Valette C Tessonnier L Mazieres J Zalcman G Brosseau S Le Moulec S Leroy L Duchemann B Lefebvre C Veillon R Westeel V Koscielny S Champiat S Ferté C Planchard D Remon J Boucher ME Gazzah A Adam J Bria E Tortora G Soria JC Besse B Caramella C Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy JAMA Oncol 2018 4 1543 1552 10.1001/jamaoncol.2018.3676 30193240 Gainor JF Shaw AT Sequist LV Fu X Azzoli CG Piotrowska Z Huynh TG Zhao L Fulton L Schultz KR Howe E Farago AF Sullivan RJ Stone JR Digumarthy S Moran T Hata AN Yagi Y Yeap BY Engelman JA Mino-Kenudson M EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis Clin Cancer Res 2016 22 4585 4593 10.1158/1078-0432.CCR-15-3101 27225694 Herbst RS Baas P Kim DW Felip E Pérez-Gracia JL Han JY Molina J Kim JH Arvis CD Ahn MJ Majem M Fidler MJ de Castro G Jr., Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Lancet 2016 387 1540 1550 10.1016/S0140-6736(15)01281-7 26712084 Huang X Chen Z Zhang N Zhu C Lin X Yu J Chen Z Lan P Wan Y Increase in CD4(+)FOXP3(+) regulatory T cell number and upregulation of the HGF/c-Met signaling pathway during the liver metastasis of colorectal cancer Oncol Lett 2020 20 2113 2118 10.3892/ol.2020.11785 32782528 Inoue T Tamiya M Tamiya A Nakahama K Taniguchi Y Shiroyama T Isa SI Nishino K Kumagai T Kunimasa K Kimura M Suzuki H Hirashima T Atagi S Imamura F Analysis of early death in japanese patients with advanced non-small-cell lung cancer treated with nivolumab Clin Lung Cancer 2018 19 e171 e176 10.1016/j.cllc.2017.09.002 29133121 Kamada T Togashi Y Tay C Ha D Sasaki A Nakamura Y Sato E Fukuoka S Tada Y Tanaka A Morikawa H Kawazoe A Kinoshita T Shitara K Sakaguchi S Nishikawa H PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer Proc Natl Acad Sci U S A 2019 116 9999 10008 10.1073/pnas.1822001116 31028147 Kang DH Chung C Sun P Lee DH Lee SI Park D Koh JS Kim Y Yi HS Lee JE Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors Cancer Immunol Immunother 2022 71 579 588 10.1007/s00262-021-03018-y 34278517 Kato S Goodman A Walavalkar V Barkauskas DA Sharabi A Kurzrock R Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate Clin Cancer Res 2017 23 4242 4250 10.1158/1078-0432.CCR-16-3133 28351930 Kim JY Lee KH Kang J Borcoman E Saada-Bouzid E Kronbichler A Hong SH de Rezende LFM Ogino S Keum N Song M Luchini C van der Vliet HJ Shin JI Gamerith G Hyperprogressive disease during anti-PD-1 (PDCD1)/PD-L1 (CD274) Therapy: a systematic review and meta-analysis Cancers (basel). 2019 11 11 1699 10.3390/cancers11111699 31683809 Kim Y Kim CH Lee HY Lee SH Kim HS Lee S Cha H Hong S Kim K Seo SW Sun JM Ahn MJ Ahn JS Park K Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced non-small cell lung cancer treated with immune checkpoint inhibitor J Thorac Oncol 2019 14 1608 1618 10.1016/j.jtho.2019.05.033 31195179 Kim KH Hur JY Koh J Cho J Ku BM Koh JY Sun JM Lee SH Ahn JS Park K Ahn MJ Shin EC Immunological characteristics of hyperprogressive disease in patients with non-small cell lung cancer treated with anti-PD-1/PD-L1 Abs Immune Netw 2020 20 e48 10.4110/in.2020.20.e48 33425433 Kim SR Chun SH Kim JR Kim SY Seo JY Jung CK Gil BM Kim JO Ko YH Woo IS Shim BY Hong SH Kang JH The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy BMC Cancer 2021 21 19 10.1186/s12885-020-07727-y 33402127 Ku BM Kim Y Lee KY Kim SY Sun JM Lee SH Ahn JS Park K Ahn MJ Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer Eur J Immunol 2021 51 956 964 10.1002/eji.202048966 33506525 Kumagai S Togashi Y Kamada T Sugiyama E Nishinakamura H Takeuchi Y Vitaly K Itahashi K Maeda Y Matsui S Shibahara T Yamashita Y Irie T Tsuge A Fukuoka S Kawazoe A Udagawa H Kirita K Aokage K Ishii G Kuwata T Nakama K Kawazu M Ueno T Yamazaki N Goto K Tsuboi M Mano H Doi T Shitara K Nishikawa H The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies Nat Immunol 2020 21 1346 1358 10.1038/s41590-020-0769-3 32868929 Kumagai S Koyama S Itahashi K Tanegashima T Lin YT Togashi Y Kamada T Irie T Okumura G Kono H Ito D Fujii R Watanabe S Sai A Fukuoka S Sugiyama E Watanabe G Owari T Nishinakamura H Sugiyama D Maeda Y Kawazoe A Yukami H Chida K Ohara Y Yoshida T Shinno Y Takeyasu Y Shirasawa M Nakama K Aokage K Suzuki J Ishii G Kuwata T Sakamoto N Kawazu M Ueno T Mori T Yamazaki N Tsuboi M Yatabe Y Kinoshita T Doi T Shitara K Mano H Nishikawa H Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments Cancer Cell 2022 40 2 201 218 10.1016/j.ccell.2022.01.001 35090594 Lee CK Man J Lord S Links M Gebski V Mok T Yang JC Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis J Thorac Oncol 2017 12 403 407 10.1016/j.jtho.2016.10.007 27765535 Lee JC Mehdizadeh S Smith J Young A Mufazalov IA Mowery CT Daud A Bluestone JA Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis Sci Immunol. 2020 5 52 eaba0759 10.1126/sciimmunol.aba0759 33008914 Lo Russo G Moro M Sommariva M Cancila V Boeri M Centonze G Ferro S Ganzinelli M Gasparini P Huber V Milione M Porcu L Proto C Pruneri G Signorelli D Sangaletti S Sfondrini L Storti C Tassi E Bardelli A Marsoni S Torri V Tripodo C Colombo MP Anichini A Rivoltini L Balsari A Sozzi G Garassino MC Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade Clin Cancer Res 2019 25 989 999 10.1158/1078-0432.CCR-18-1390 30206165 Mok TSK Wu YL Kudaba I Kowalski DM Cho BC Turna HZ Castro G Jr Srimuninnimit V Laktionov KK Bondarenko I Kubota K Lubiniecki GM Zhang J Kush D Lopes G Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Lancet 2019 393 1819 1830 10.1016/S0140-6736(18)32409-7 30955977 Offin M Rizvi H Tenet M Ni A Sanchez-Vega F Li BT Drilon A Kris MG Rudin CM Schultz N Arcila ME Ladanyi M Riely GJ Yu H Hellmann MD Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers Clin Cancer Res 2019 25 1063 1069 10.1158/1078-0432.CCR-18-1102 30045933 Passaro A Novello S Giannarelli D Bria E Galetta D Gelibter A Reale ML Carnio S Vita E Stefani A Pizzutilo P Stati V Attili I de Marinis F Early progression in non-small cell lung cancer (NSCLC) with high PD-L1 treated with pembrolizumab in first-line setting: a prognostic scoring system based on clinical features Cancers (basel). 2021 13 12 2935 10.3390/cancers13122935 34208253 Reck M Rodriguez-Abreu D Robinson AG Hui R Csoszi T Fulop A Gottfried M Peled N Tafreshi A Cuffe S O'Brien M Rao S Hotta K Leiby MA Lubiniecki GM Shentu Y Rangwala R Brahmer JR Investigators K Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer N Engl J Med 2016 375 1823 1833 10.1056/NEJMoa1606774 27718847 Rittmeyer A Barlesi F Waterkamp D Park K Ciardiello F von Pawel J Gadgeel SM Hida T Kowalski DM Dols MC Cortinovis DL Leach J Polikoff J Barrios C Kabbinavar F Frontera OA De Marinis F Turna H Lee JS Ballinger M Kowanetz M He P Chen DS Sandler A Gandara DR Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Lancet 2017 389 255 265 10.1016/S0140-6736(16)32517-X 27979383 Sacdalan DB Lucero JA Sacdalan DL Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis Onco Targets Ther 2018 11 955 965 10.2147/OTT.S153290 29503570 Sharpnack MF Cho JH Johnson TS Otterson GA Shields PG Huang K Carbone DP He K Clinical and molecular correlates of tumor mutation burden in non-small cell lung cancer Lung Cancer 2020 146 36 41 10.1016/j.lungcan.2020.05.021 32505734 Zou XL Li XB Ke H Zhang GY Tang Q Yuan J Zhou CJ Zhang JL Zhang R Chen WY Prognostic value of neoantigen load in immune checkpoint inhibitor therapy for cancer Front Immunol 2021 12 689076 10.3389/fimmu.2021.689076 34992591